These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 27991734)

  • 1. Advocates call for long-term extension of the FDA's rare pediatric disease priority review program: Federal voucher program considered instrumental in shortening drug review, approval period.
    Am J Med Genet A; 2017 Jan; 173(1):7-8. PubMed ID: 27991734
    [No Abstract]   [Full Text] [Related]  

  • 2. Impact Of The Priority Review Voucher Program On Drug Development For Rare Pediatric Diseases.
    Hwang TJ; Bourgeois FT; Franklin JM; Kesselheim AS
    Health Aff (Millwood); 2019 Feb; 38(2):313-319. PubMed ID: 30715972
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Analysis of the first ten years of FDA's rare pediatric disease priority review voucher program: designations, diseases, and drug development.
    Mease C; Miller KL; Fermaglich LJ; Best J; Liu G; Torjusen E
    Orphanet J Rare Dis; 2024 Feb; 19(1):86. PubMed ID: 38403586
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Experience With the Priority Review Voucher Program for Drug Development.
    Kesselheim AS; Maggs LR; Sarpatwari A
    JAMA; 2015 Oct; 314(16):1687-8. PubMed ID: 26414802
    [No Abstract]   [Full Text] [Related]  

  • 5. Women's health advocates dismayed at FDA's Plan B decision.
    Ready T
    Nat Med; 2005 Oct; 11(10):1016. PubMed ID: 16211017
    [No Abstract]   [Full Text] [Related]  

  • 6. Regulators adopt more orphan drugs.
    Reardon S
    Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
    [No Abstract]   [Full Text] [Related]  

  • 7. Federal Right-to-Try Legislation - Threatening the FDA's Public Health Mission.
    Joffe S; Lynch HF
    N Engl J Med; 2018 Feb; 378(8):695-697. PubMed ID: 29320302
    [No Abstract]   [Full Text] [Related]  

  • 8. Is the priority review voucher program stimulating new drug development for tropical diseases?
    Kerr KW; Henry TC; Miller KL
    PLoS Negl Trop Dis; 2018 Aug; 12(8):e0006695. PubMed ID: 30092022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The needs of the few.
    Nature; 2010 Jul; 466(7303):160. PubMed ID: 20613796
    [No Abstract]   [Full Text] [Related]  

  • 10. Characteristics of rare disease marketing applications associated with FDA product approvals 2006-2010.
    Pariser AR; Slack DJ; Bauer LJ; Warner CA; Tracy LA
    Drug Discov Today; 2012 Aug; 17(15-16):898-904. PubMed ID: 22564486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Orphanage at the FDA.
    Chen E
    J Cardiovasc Transl Res; 2012 Oct; 5(5):735-6. PubMed ID: 21080134
    [No Abstract]   [Full Text] [Related]  

  • 12. The Pediatric Research Equity Act Moves Into Adolescence.
    Bourgeois FT; Hwang TJ
    JAMA; 2017 Jan; 317(3):259-260. PubMed ID: 28114560
    [No Abstract]   [Full Text] [Related]  

  • 13. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs.
    Farrell AT; Goldberg KB; Pazdur R
    Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876
    [No Abstract]   [Full Text] [Related]  

  • 14. Losing deference in the FDA's second century: judicial review, politics, and a diminished legacy of expertise.
    O'Reilly JT
    Cornell Law Rev; 2008 Jul; 93(5):939-80. PubMed ID: 18618965
    [No Abstract]   [Full Text] [Related]  

  • 15. Preserve the FDA's authority.
    Guharoy R
    Am J Health Syst Pharm; 1996 Nov; 53(21):2636, 2638. PubMed ID: 8913395
    [No Abstract]   [Full Text] [Related]  

  • 16. "Creating hope" and other incentives for drug development for children.
    Connor E; Cure P
    Sci Transl Med; 2011 Jan; 3(66):66cm1. PubMed ID: 21248312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FDA's accelerated approval process: does the pharmaceutical industry have adequate incentives for self-regulation?
    Orlando VI
    Am J Law Med; 1999; 25(4):543-68. PubMed ID: 10629734
    [No Abstract]   [Full Text] [Related]  

  • 19. The impact of the Orphan Drug Act on the development and advancement of neurological products for rare diseases: a descriptive review.
    Burke KA; Freeman SN; Imoisili MA; Coté TR
    Clin Pharmacol Ther; 2010 Oct; 88(4):449-53. PubMed ID: 20856241
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Moment of reckoning.
    Wadman M
    Nature; 2007 Apr; 446(7138):844-5. PubMed ID: 17443154
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.